Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019

PR Newswire

VANCOUVER, BC, Jan. 14, 2022

FN Media Group Presents USA News Group News Commentary

VANCOUVER, BC, Jan. 14, 2022 /PRNewswire/ -- USA News Group - Cancer cases are on the rise, according to a new study comparing the number of cancer diagnoses globally in 2010 and 2019. Among the data, researchers witnessed that global cancer rates were up by +26% and that breast cancer was the leading cause of cancer-related disability-adjusted life years (DALYs), deaths, and years of life lost (YLLs) among females globally in 2019. According to Research and Markets, the global breast cancer drugs market is expected to grow to $19.49 billion by 2025 at a CAGR of 7.1%. Among the biotech developers working into 2022 on new treatments for breast cancer are Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Roche Holding AG (OTC:RHHBY), Pfizer Inc. (NYSE:PFE), Incyte Corporation (NASDAQ:INCY) and AstraZeneca PLC (NASDAQ:AZN).

Among the cancers being targeted by Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship immunotherapeutic agent pelareorep, breast cancer is the company's official primary focus, according to its latest letter to shareholders that reviewed its accomplishments in 2021, and outlined its upcoming 2022 program.

Within its Breast Cancer Program so far, Oncolytics has witnessed a more-than-doubling of overall survival in metastatic HR+/HER2- breast cancer patients treated with pelareorep in IND-213—as seen from study results delivered in 2017.

After analyzing the data more, Oncolytics chose to focus on three achievable objectives put in place by regulators and the company's pharma partners, representing important steps towards a registrational study. This included: 1. Confirming that pelareorep works through an immunotherapeutic mechanism of action; 2. Determining whether pelareorep synergizes with immune checkpoint inhibitors; and 3. Identifying a biomarker to select patients who are likely to have better clinical outcomes.

According to Dr. Matt Coffey, President & CEO of Oncolytics Biotech, as per the letter: "I am pleased to report that we are well on our way to achieving these three objectives."

As of April 2021, Oncolytics presented cohort data from its AWARE-1 study, being conducted with Roche Holding AG (OTC:RHHBY), showing the company had achieved the first two objectives referenced above.

Later in December at the 2021 San Antonio Breast Cancer Symposium (SABCS), Oncolytics presented a positive safety update from its IRENE Phase 2 Triple-Negative Breast Cancer Trial evaluating the safety and efficacy of pelareorep in combination with the anti-PD-1 checkpoint inhibitor retifanlimab from Incyte Corporation (NASDAQ:INCY) for second- or third-line treatment of patients with metastatic triple-negative breast cancer (TNBC).

Safety data from the trial showed the combination was well-tolerated, with no safety concerns noted in any of the patients enrolled in the trial at the time of reporting.

"Prior clinical studies have shown that pelareorep upregulates tumor PD-L1 expression and reverses immunosuppressive TMEs," said Mridula George, M.D., Medical Oncologist, Rutgers Cancer Institute of New Jersey, Assistant Professor of Medicine, Rutgers Robert Wood Johnson Medical School, and principal investigator of the trial. "These findings suggest that pelareorep can address a pressing unmet need in TNBC by synergizing with PD-1 inhibition to increase the proportion of patients responding to therapy. We look forward to evaluating this hypothesis through the IRENE study's continued advancement and are pleased that the pelareorep-retifanlimab combination has been well-tolerated in each of the patients enrolled in the trial."

The IRENE study remains ongoing and will continue to enroll patients at the Rutgers Cancer Institute of New Jersey and the Ohio State University Comprehensive Cancer Center.

Incyte Corporation (NASDAQ:INCY) recently gave another update involving its retifanlimab in combination with BriaCell Therapeutics' lead clinical candidate Bria-IMTTM at the SABCS. Summarized in the update, the overall survival was much higher in the patients in the combination study, suggesting an additive or synergistic effect and supporting the continuation of the study. According to BriaCell's website, further safety and efficacy data is expected through 2022.

Pfizer, Inc. (NYSE:PFE) recently entered into a clinical trial collaboration and supply agreement with Celcuity, where the pharma giant will provide Palbociclib (Ibrance) for use in a phase 3 clinical study being conducted by Celcuity at no cost to the company.

"We are excited that Pfizer is providing palbociclib for this important phase 3 clinical trial," said Brian Sullivan, chief executive officer and co-founder of Celcuity. "Our goal is to address the significant unmet need for new therapeutic options for patients who progressed on their first line of treatment for ER-positive/HER2-negative advanced breast cancer."

The phase 3 clinical trial is expected to launch in the first half of 2022 assessing the use of the pan-PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with palbociclib and fulvestrant for patients with estrogen receptor (ER)–positive, HER2-negative advanced breast cancer. Celcuity will release further details about the clinical trial following discourse and subsequent feedback from the FDA.

Towards the end of 2021, AstraZeneca PLC (NASDAQ:AZN) and partners Daiichi Sankyo announced that the European Medicines Agency (EMA) had validated its Type II Variation Application for trastuzumab deruxtecan (T-DXd; Enhertu) for the treatment of advanced, previously treated HER2-positive breast cancer patients.

Meanwhile, the first patient with HR+, HER2- inoperable metastatic breast cancer was dosed with datopotamab deruxtecan (DS-1062a; dato-DXd) as part of the phase 3 TROPION-Breast01 trial (NCT05104866). The TROP2-directed DXd ADC that is currently being developed by Daiichi Sankyo and AstraZeneca is currently under investigation in the global, randomized, open-label trial at a dose of 6 mg/kg vs investigator's choice of chemotherapy.

"Most patients with HR-positive, HER2-negative metastatic breast cancer will inevitably progress on available treatments, including hormonal therapy and standard-of-care chemotherapy," said Cristian Massacesi, MD, chief medical officer and oncology chief development officer at AstraZeneca. "The TROPION-Breast01 trial will evaluate whether datopotamab deruxtecan may be a more effective treatment than chemotherapy for patients with previously treated HR-positive, HER2-negative advanced breast cancer previously treated with 1 to 2 lines of chemotherapy."

Another method of improving chances in the fight against cancer, is the race to improve early detections. According to the Carol Milgard Breast Center early detection is key.

Roche Holding AG (OTC:RHHBY) recently kicked in $290 million into a funding round that surpassed $1 billion into liquid biopsy developers Freenome

"We are happy to support Freenome's innovative approach to early cancer detection," said Thomas Schinecker, CEO of Roche Diagnostics. "We believe blood-based multimodal screening and data-driven medical insights will help deliver personalized healthcare. This investment will be an important step to advance early cancer screening, and we look forward to joining Freenome in this journey."

For more information go to: https://usanewsgroup.com/2020/02/24/why-biotechnology-companies-are-so-important/ 

Article Source: 

USA News Group
http://USAnewsgroup.com
info@usanewsgroup.com

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.

While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:  
editor@financialnewsmedia.com 
U.S. Phone: +1(954)345-0611

Voltar noticias em Inglês